New Drug Submission and Compliance Services for Canada

Canadian Drug Regulatory Landscape

Bringing a new, innovative pharmaceutical product to the Canadian market requires strict adherence to the robust regulatory framework established by Health Canada. As the national authority responsible for regulating health products, Health Canada ensures that drugs available to Canadians are safe, effective, and manufactured to the highest quality standards.

For pharmaceutical innovators, navigating this landscape involves a comprehensive understanding of the Food and Drugs Act and its associated regulations. The submission process is a critical milestone that demands meticulous preparation, scientific rigor, and strategic planning to ensure that the drug's safety, efficacy, and quality are thoroughly demonstrated. Effective management of this process is not merely a legal requirement but a crucial factor in achieving timely market access and securing a competitive advantage in the Canadian healthcare environment.

The Structured Approach to Market Authorization

To obtain a Notice of Compliance (NOC) and a Drug Identification Number (DIN) in Canada, pharmaceutical companies must submit a detailed dossier to the Therapeutic Products Directorate (TPD), a branch of Health Canada. The dossier must follow the International Council for Harmonisation (ICH) Common Technical Document (CTD) format, which is globally recognized and facilitates a harmonized review process. This structure requires the organization of data into five distinct modules, covering administrative information, summaries, quality data (chemistry, manufacturing, and controls), non-clinical studies, and clinical study reports. The review process entails a rigorous assessment of this data to determine the product's risk-benefit profile, ensuring that the therapeutic benefits outweigh any potential risks to the patient population.

• Dossier Preparation and Organization

Compiling comprehensive data modules regarding chemistry, manufacturing, controls, and clinical safety/efficacy in compliance with ICH standards.

• Health Canada Scientific Review

A meticulous evaluation of the submission package by TPD scientists to ensure the product meets Canadian safety and efficacy standards.

• Compliance with Good Manufacturing Practices (GMP)

Adhering to strict Canadian GMP requirements for the manufacturing, packaging, and testing of the drug product to ensure consistency and quality.

Proregulations' New Drug Submission Services

We provide expert guidance to bridge the gap between innovation and regulatory compliance within the Canadian market. Our comprehensive services include:

• Strategic regulatory planning
  We develop tailored strategies for your NDS, optimizing the pathway to market authorization in Canada and proactively addressing potential bottlenecks.
• Dossier compilation and publishing
  Our experts compile, review, and format the technical documentation in the required CTD format, ensuring accuracy, consistency, and compliance with Health Canada guidelines.
• Health Canada liaison and query management
  We act as the primary contact with regulatory authorities, managing all correspondence, including pre-submission meetings and prompt responses to Information Requests (IRs).
• Lifecycle management support
  We assist with post-approval compliance, including drug identification number (DIN) maintenance, annual drug notification submissions, and post-market safety reporting requirements.

If you are looking to accelerate your product entry into the Canadian market with expert regulatory support, please feel free to contact us.